Global Chronic Hand Eczema (CHE) Markets, Epidemiology, Drugs, Pipeline and Forecast to 2030

DUBLIN, March 24, 2020 /PRNewswire/ -- The "Chronic Hand Eczema (CHE) - Market Insights, Epidemiology, and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

The market size of CHE in the seven major markets was worth USD 728.41 Million in 2017.

This report delivers an in-depth understanding of the Chronic Hand Eczema (CHE), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Hand Eczema (CHE) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted CHE symptoms market Size from 2017 to 2030 segmented by seven major markets. The The report also covers current Chronic Hand Eczema (CHE) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Study Period: 2017-2030

Chronic Hand Eczema (CHE) Epidemiology

The CHE symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of Chronic Hand Eczema (CHE) in the 7MM was found to be 4,229,215 in 2017. The prevalence of Chronic Hand Eczema (CHE) in the 7MM is expected to increase during the study period of 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenarios of Chronic Hand Eczema (CHE) in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030. The epidemiology has segmented into Total Prevalent cases of Chronic Hand Eczema, Gender-Specific cases of Chronic Hand Eczema, Diagnosed Cases of Chronic Hand Eczema, and Age-Specific cases of Chronic Hand Eczema, Severity Specific Cases of Chronic Hand Eczema and Subgroup Specific Cases of Chronic Hand Eczema.

As per the National Eczema Association, Hand Eczema/Hand Dermatitis is a very common condition affecting up to 10% of the population. Chronic Hand Eczema is estimated to occur in 5-7% of patients with Hand Eczema. Among these, Severe chronic HE has a major adverse impact on economic and social functions.

Chronic Hand Eczema (CHE) Drug Chapters

The drug chapter segment of the Chronic Hand Eczema (CHE) report encloses the detailed analysis of CHE marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Hand Eczema (CHE) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Chronic Hand Eczema (CHE) Marketed Drugs

Toctino: Alitretinoin

It acts as a pan-agonist of retinoid receptors which was developed by Basilea Pharmaceutica and has been specifically developed for severe CHE. It is only available in the EU, Canada and other regions for the treatment of severe chronic hand eczema (CHE), refractory to treatment with a potent topical corticosteroid. The product is widely accepted and included in the NICE guidelines to treat the CHE. However, there is no approved systemic therapy available in the US and Japan for the treatment of corticosteroid resistant CHE.

Chronic Hand Eczema (CHE) Emerging Drugs

To counter the current unmet needs, the market is hoping to provide better treatment options for CHE. With the continuous efforts in research and development, few companies are developing therapies such as LEO Pharma, Asana Biosciences, Afecta Therapeutics, Regeneron Pharmaceuticals/Sanofi, NUVO research, and Aralez Pharmaceuticals. Post 2023 the market is expected to witness rapid growth due to the expected launch of emerging therapies, with a novel class of drugs such as Delgocitinib (LEO Pharma/ Japan Tobacco), ASN002 (Asana Biosciences), Dupilumab (Regeneron/Sanofi). These drugs are targeting most of the refractory pool of the CHE.

Chronic Hand Eczema (CHE) Market Outlook

The Chronic Hand Eczema (CHE) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic Hand Eczema (CHE) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Hand Eczema (CHE) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Hand Eczema (CHE) key players involved in developing targeted therapeutics.

Competitive Intelligence Analysis

This report was created using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of CHE, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
• Comprehensive insight has been provided into the Chronic Hand Eczema (CHE) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Hand Eczema (CHE) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Chronic Hand Eczema (CHE) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Hand Eczema (CHE) market

Report Highlights

• In the coming years, Chronic Hand Eczema (CHE) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hand Eczema (CHE) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for CHE. Launch of emerging therapies will significantly impact the Chronic Hand Eczema (CHE) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CHE

Report Insights

• Patient Population
• Therapeutic Approaches
• Chronic Hand Eczema (CHE) Pipeline Analysis
• Chronic Hand Eczema (CHE) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Chronic Hand Eczema (CHE) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Companies Mentioned

• Basilea Pharmaceutica/ Stiefel Laboratories
• LEO Pharma/Japan Tobacco
• Asana Biosciences
• Regeneron Pharmaceuticals/Sanofi

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sf6brc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-chronic-hand-eczema-che-markets-epidemiology-drugs-pipeline-and-forecast-to-2030-301028873.html

SOURCE Research and Markets